Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Faculty Members have conducted research related to the Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial
Farzin Rezaei
Farzin Rezaei

Professor of Psychiatry

Department Psychiatry

School of Medicine

Roozbeh Hospital

Tehran University of Medical Sciences

All Documents
1. Clinical Cut Scores for the Persian Version of the Personality Inventory for Dsm-5, Journal of Clinical Psychology (2024)
2. Improvement of Psychotherapy Training in the Psychiatric Residency Program in Iran, Academic Psychiatry (2024)
3. Meta-Analytic Review of Temperamental Correlates of the Five-Factor Model and Hierarchical Taxonomy of Psychopathology Domains, Indian Journal of Psychological Medicine (2024)
4. The Sensitivity of the Icd-11 Trait Model to the Symptoms of Clinical Disorders in Young Adults, Personality and Mental Health (2024)
5. A Head-To-Head Comparison of Eight Unique Personality Systems in Predicting Somatization Phenomenon, BMC Psychiatry (2023)
6. Construct and Criterion Validity of the Hitop Spectra to Predict Dimensional and Categorical Somatization in a Large Non-Western Sample, Scientific Reports (2023)
7. Comparison of the Relative Sensitivity of Two Dimensional Personality Models to the Psychopathological Symptoms: The Section Iii Dsm-5 Maladaptive Traits Versus Affective Temperaments, BMC Psychiatry (2022)
8. Efficacy of Melatonin As an Adjunct in the Treatment of Acute Mania: A Double-Blind and Placebo-Controlled Trial, International Clinical Psychopharmacology (2020)
9. Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial, International Journal of Neuropsychopharmacology (2020)
10. Resveratrol As Adjunctive Therapy in Treatment of Irritability in Children With Autism: A Double-Blind and Placebo-Controlled Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2020)
11. Vortioxetine As Adjunctive Therapy to Risperidone for Treatment of Patients With Chronic Schizophrenia: A Randomised, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Psychopharmacology (2020)
12. Amantadine As Adjuvant Therapy in the Treatment of Moderate to Severe Obsessive–Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, Psychiatry and Clinical Neurosciences (2019)
13. Citicoline (Cdp-Choline) Add-On Therapy to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial, Human Psychopharmacology (2018)
14. A Survey on Mental Health Status of Adult Population Aged 15 and Above in the Province of Fars, Iran, Archives of Iranian Medicine (2017)
15. Cilostazol Adjunctive Therapy in Treatment of Negative Symptoms in Chronic Schizophrenia: Randomized, Double-Blind, Placebo-Controlled Study, Human Psychopharmacology (2017)
16. Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind, Randomized Clinical Trial, Iranian Journal of Psychiatry (2017)
17. L-Carnosine As an Adjuvant to Fluvoxamine in Treatment of Obsessive Compulsive Disorder: A Randomized Double-Blind Study, Human Psychopharmacology (2017)
18. Pregnenolone As an Adjunct to Risperidone for Treatment of Women With Schizophrenia: A Randomized Double-Blind Placebo-Controlled Clinical Trial, Journal of Psychiatric Research (2017)
19. Simvastatin Adjunct Therapy for Negative Symptoms of Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial, International Clinical Psychopharmacology (2017)
20. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study, Pharmacopsychiatry (2016)
21. Celecoxib Adjunctive Therapy for Acute Bipolar Mania: A Randomized, Double-Blind, Placebo-Controlled Trial, Bipolar Disorders (2015)
22. Sustained-Release Methylphenidate in Methamphetamine Dependence Treatment: A Double-Blind and Placebo-Controlled Trial, DARU# Journal of Pharmaceutical Sciences (2015)
23. Sustained-Release Methylphenidate in Methamphetamine Dependence Treatment: A Double-Blind and Placebo-Controlled Trial, DARU, Journal of Pharmaceutical Sciences (2015)